STAT6 correlates with response to immune checkpoint blockade therapy and predicts worse survival in thyroid cancer.

Conclusion: STAT6 may act as a prognostic biomarker and provide useful information for immunotherapy in thyroid carcinoma.
PMID: 32940081 [PubMed - in process]

Source: Future Medicine: Biomarkers in Medicine - September 19, 2020 Category: Internal Medicine Tags: Biomark Med Source Type: research